Calidi Biotherapeutics, Inc.
CLDI
$1.49
-$0.01-0.73%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.15M | -5.72M | -4.99M | -4.10M | -5.05M |
| Total Depreciation and Amortization | 427.00K | 407.00K | 394.00K | 393.00K | 390.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | 4.00K | 9.00K |
| Total Other Non-Cash Items | 597.00K | 495.00K | 496.00K | 527.00K | 297.00K |
| Change in Net Operating Assets | -113.00K | -67.00K | -3.04M | -2.25M | -588.00K |
| Cash from Operations | -4.24M | -4.88M | -7.13M | -5.42M | -4.95M |
| Capital Expenditure | -27.00K | -57.00K | -7.00K | -5.00K | -6.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -27.00K | -57.00K | -7.00K | -5.00K | -6.00K |
| Total Debt Issued | -- | -- | -- | 0.00 | 600.00K |
| Total Debt Repaid | -404.00K | -392.00K | -1.67M | -19.00K | -18.00K |
| Issuance of Common Stock | 6.09M | 3.00K | 10.08M | 13.63M | 3.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.79M | -80.00K | -301.00K | -502.00K | 1.73M |
| Cash from Financing | 9.48M | -469.00K | 8.11M | 13.11M | 6.05M |
| Foreign Exchange rate Adjustments | 0.00 | 6.00K | -- | 16.00K | -33.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.22M | -5.40M | 970.00K | 7.69M | 1.06M |